 | Up a level |
Davids, Matthew Steven, Seymour, John Francis, Roberts, Andrew Warwick, Eichhorst, Barbara, Kipps, Thomas J., Mato, Anthony R., Stilgenbauer, Stephan, Mobasher, Mehrdad, Desai, Monali Bhardwaj, Potluri, Jalaja, Pena, German E., Verdugo, Maria E., Nielsen, Jacqueline, Cyr, Aimee, Fleming, Leanne Lash and Hallek, Michael J. (2018). Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Hillmen, Peter, Kater, Arnon P., Seymour, John Francis, Langerak, Anton W., Eichhorst, Barbara, Owen, Carolyn, Assouline, Sarit E., Janssens, Ann, Marlton, Paula, Badoux, Xavier C., Mous, Rogier, Chyla, Brenda, Humerickhouse, Rod, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Punnoose, Elizabeth, Wang, Jue, Wu, Qun Jenny and Mobasher, Mehrdad (2018). High, durable minimal residual disease negativity (MRD-) with venetoclax plus rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Mobasher, Mehrdad, Huang, Jane, Elstrom, Rebecca L., Elhamy, Mostafa, Bernaards, Coen, Hallek, Michael J., Hillmen, Peter, Kater, Arnon Philip, Kipps, Thomas J. and Seymour, John Francis (2014). Multicenter, phase III, open-label, randomized study in relapsed/refractory CLI, to evaluate the benefit of GDC-0199 (ABT-199) plus rituximah compared with bendamustine plus rituximab. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755